Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia
and features dormant and discontinued projects.
The report reviews key players involved in the therapeutics development for B-Cell Chronic Lymphocytic Leukemia
and enlists all their major and minor projects
Differences in gene expression between B-cell chronic lymphocytic leukemia
and normal B cells: a meta-analysis of three microarray studies.
Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia
The United States Food and Drug Administration recently authorized Alexion's Investigational New Drug application for a clinical trial of ALXN6000 as a treatment for patients with refractory or relapsing B-cell Chronic Lymphocytic Leukemia
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia
The drug is currently not approved for the treatment of multiple sclerosis but is indicated for treating B-cell chronic lymphocytic leukemia
in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
a unit of German-based Schering AG, and is currently FDA-approved to treat a type of leukemia, B-cell chronic lymphocytic leukemia
24) Soluble CD44 has been found in the serum of patients with various metastasized cancers and hematologic malignancies (12) such as B-cell chronic lymphocytic leukemia
, (25) acute leukemias, (26) myelodysplastic syndromes, and NHL, and in some cases was associated with a poor clinical outcome.
15 January 2010 - US-based biopharmaceutical company CytRx Corporation (NASDAQ:CYTR) said on Wednesday it plans to initiate a Phase II proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib (formerly known as INNO-406) in patients with high-risk B-cell chronic lymphocytic leukemia